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Abstract The premature cancer mortality rate has been declining in Canada, but there has
been considerable variation in the rate of decline across cancer sites. I analyze the effect that
pharmaceutical innovation had on premature cancer mortality in Canada during the period
2000–2011, by investigating whether the cancer sites that experienced more pharmaceutical
innovation had larger declines in the premature mortality rate, controlling for changes in
the incidence rate. Premature mortality before age 75 is significantly inversely related to
the cumulative number of drugs registered at least 10 years earlier. Since mean utilization
of drugs that have been marketed for less than 10 years is only one-sixth as great as mean
utilization of drugs that have been marketed for at least a decade, it is not surprising that
premature mortality is strongly inversely related only to the cumulative number of drugs that
had been registered at least ten years earlier. Premature mortality before age 65 and 55 is
also strongly inversely related to the cumulative number of drugs that had been registered at
least ten years earlier. None of the estimates of the effect of incidence on mortality are statis-
tically significant. Controlling for the cumulative number of drugs, the cumulative number
of chemical subgroups does not have a statistically significant effect on premature mortality.
This suggests that drugs (chemical substances) within the same class (chemical subgroup)
are not therapeutically equivalent. During the period 2000–2011, the premature (before age
75) cancer mortality rate declined by about 9%. The estimates imply that, in the absence
of pharmaceutical innovation during the period 1985–1996, the premature cancer mortality
rate would have increased about 12% during the period 2000–2011. A substantial decline
in the “competing risk” of death from cardiovascular disease could account for this. The
estimates imply that pharmaceutical innovation during the period 1985–1996 reduced the
number of years of potential life lost to cancer before age 75 in 2011 by 105,366. The cost
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per life-year before age 75 gained from previous pharmaceutical innovation is estimated to
have been 2730 USD. Most of the previously-registered drugs were off-patent by 2011, but
evidence suggests that, even if these drugs had been sold at branded rather than generic prices,
the cost per life-year gained would have been below 11,000 USD, a figure well below even
the lowest estimates of the value of a life-year gained. The largest reductions in premature
mortality occur at least a decade after drugs are registered, when their utilization increases
significantly. This suggests that, if Canada is to obtain substantial additional reductions in
premature cancer mortality in the future (a decade or more from now) at a modest cost,
pharmaceutical innovation (registration of new drugs) is needed today.
Keywords Cancer · Neoplasm · Mortality · Longevity · Pharmaceutical · Chemotherapy ·
Innovation · Canada
1 Introduction
Previous authors have argued that “reducing premature mortality is a crucial public health
objective” (Renard et al. 2014). A widely used measure of premature mortality is years of
potential life lost (YPLL) before a given age (e.g. age 75), i.e. the number of years not lived
by an individual who died before that age (Association of Public Health Epidemiologists
in Ontario 2015). Statistics of YPLL are published by the World Health Organization, the
OECD, and government agencies of Canada, the U.S., and other countries. Burnet et al.
(2005) argue that YPLL “should be considered when allocating research funds.” In the U.S.,
“cancer [was] responsible for more [YPLL] than all other causes of death combined” in 2008
(National Cancer Institute 2015c). In Canada, premature (before age 75) mortality from
cancer is about twice as great as premature mortality from circulatory diseases.
But as shown in Fig. 1, the premature cancer mortality rate has been declining; it declined
about 20% between 1996 and 2006. The cancer incidence rate remained approximately
constant during that period.
While the premature mortality rate from all cancers combined has been declining in
Canada, Fig. 2 indicates that there has been considerable variation in the rate of decline across
cancer sites. During the period 2000–2011, the premature mortality rate from breast cancer
declined 20%, and from cancer of lymphoid, haematopoietic and related tissue declined
27%, but the premature mortality rate from lip, oral cavity, and pharynx cancer increased
6%, and from cancer of female genital organs increased 8%. I will show that this variation
in the rate of decline of premature mortality cannot be explained by variation in the rate of
decline of incidence.
In this paper, I will analyze the effect that pharmaceutical innovation has had on premature
cancer mortality in Canada during the period 2000–2011.1,2 The analysis will be performed
using a difference-in-differences research design based on longitudinal disease-level data.
1 Lichtenberg (2014b) analyzed the impact of pharmaceutical innovation and other types ofmedical innovation
on cancer mortality in the U.S. during the period 2000–2009. But as the Squires (2011) demonstrated, the
U.S. health care system differs dramatically from the health care systems of other OECD countries, including
Canada. For example, in 2008 per capita spending on health was 85% higher in the U.S. than it was in Canada.
Also, the outcome measure and the measure of pharmaceutical innovation used in the present study will differ
from those used in Lichtenberg (2014b).
2 I use the sample period 2000–2011 to avoid potential discontinuities in the mortality data, because Canada
used the ICD9 cause-of-death classification during 1979–1999, and the ICD10 cause-of-death classification
during 2000–2011.
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C51-C58 female genital organs
C00-C14 lip, oral cavity and pharynx
C15-C26 digestive organs
C73-C75 endocrine glands and related structures
C43-C44 skin
C69-C72 eye, brain and central nervous system
C64-C68 urinary organs
C45-C49 connective and soft tissue
C30-C39 respiratory system and intrathoracic organs
C76-C80 secondary and ill-defined
C40-C41 bone and articular cartilage
C60-C63 male genital organs
C50-C50 breast
C81-C96 lymphoid, haematopoietic and related tissue
The premature mortality rate is the number of potential years of life lost before age 75 per 100,000 population age 0-74.
Fig. 2 Log change from 2000 to 2011 in the premature mortality rate, by type of cancer, Canada
In essence, I will investigate whether the cancer sites that experienced more pharmaceutical
innovation had larger declines in the premature mortality rate, controlling for changes in the
incidence rate. Figure 3 illustrates that the rate of pharmaceutical innovation, as measured
by the number of drugs registered during the period 1988–2013, varied considerably across
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C15-C26 digestive organs
C64-C68 urinary organs
C69-C72 eye, brain and central nervous system
C45-C49 connective and soft tissue
C60-C63 male genital organs
Fig. 3 Cumulative number of drugs launched in Canada for 5 types of cancer, 5-year intervals, 1988–2013
cancer sites. Only 5 drugs for cancer of the eye, brain and central nervous system were
registered, while 19 drugs for cancer of digestive organs were registered.
The analysis will be based on aggregate data—longitudinal data on 15 cancer sites3—
rather than patient-level data. Stukel et al. (2007) argue that comparisons of outcomes between
patients treated and untreated in observational studies may be biased due to differences in
patient prognosis between groups, often because of unobserved treatment selection biases. I
believe that difference-in-differences estimates based on aggregate panel data are much less
likely to be subject to unobserved treatment selection biases than estimates based on cross-
sectional patient-level data.4 Moreover, the outcome measures that we analyze (premature
mortality rates) are not subject to lead-time bias.5
In Sect. 2, I describe an econometricmodel of premature cancermortality. The data sources
used to construct the data to estimate this model are described in Sect. 3. Empirical results
are presented in Sect. 4. Key implications of the estimates are discussed in Sect. 5. Section
6 provides a summary and conclusions.
3 The 15 cancer sites are the 15malignant neoplasm ICD-10 blocks defined by theWorldHealth Organization.
4 Jalan and Ravallion (2001) argued that “aggregation to village level may well reduce measurement error or
household-specific selection bias” (p. 10).
5 Survival time for cancer patients is usually measured from the day the cancer is diagnosed until the day
they die. Patients are often diagnosed after they have signs and symptoms of cancer. If a screening test leads
to a diagnosis before a patient has any symptoms, the patient’s survival time is increased because the date of
diagnosis is earlier. This increase in survival time makes it seem as though screened patients are living longer
when that may not be happening. This is called lead-time bias. It could be that the only reason the survival
time appears to be longer is that the date of diagnosis is earlier for the screened patients. But the screened
patients may die at the same time they would have without the screening test. See National Cancer Institute
(2015a).
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2 Premature cancer mortality model
In his model of endogenous technological change, Romer (1990) hypothesized an aggregate
production function such that an economy’s output depends on the “stock of ideas” that have
previously been developed, as well as on the economy’s endowments of labor and capital.
The premature mortality model that I will estimate may be considered a health production
function, in which premature mortality is an inverse indicator of health output or outcomes,
and the cumulative number of drugs approved is analogous to the stock of ideas. The first
model will be of the following form:
ln(YPLL75st) = βkCUM_NCEs,t−k + γ ln(INC_RATE75st) + αs + δt + εst (1)
where, YPLL75st = years of potential life lost before age 75 from cancer at site s
per 100,000 population age 0–74 in year t (t = 2000, . . ., 2011); CUM_NCEi,t−k =∑
d INDds REGISTEREDd,t−k = the number of new chemical entities (drugs) to treat cancer
at site s that had been registered in Canada by the end of year t − k; INDds = 1 if drug d is
used to treat (indicated for) cancer at site s, 0 if drug d is not used to treat (indicated for)
cancer at site s; REGISTEREDd,t−k = 1 if drug d was registered in Canada by the end of year
t− k, 0 if drug d was not registered in Canada by the end of year t− k; INC_RATE75st = the
average annual incidence rate of cancer at site s per 100,000 population age 0–74 in years
t − 5, t − 4, . . ., t − 16; αi = a fixed effect for cancer at site s; δt = a fixed effect for year t.
Inclusion of year and cancer-site fixed effects controls for the overall decline in premature
cancermortality and for stable between-disease differences in prematuremortality.Anegative
and significant estimate of βk in Eq. (1) would signify that diseases for which there was more
pharmaceutical innovation had larger declines in premature mortality. The functional form
of Eq. (1) has the property of diminishing marginal productivity: the absolute reduction in
premature mortality declines with each successive increase in the number of drugs.
As illustrated by Fig. 4, the data exhibit heteroskedasticity—diseases with larger mean
premature mortality rates had smaller (positive and negative) annual percentage fluctuations
in YPLL75. Equation (1) will therefore be estimated by weighted least-squares, weighting
by the mean premature mortality rate during 2000–2011 ((tYPLL75it)/12). The standard
errors of Eq. (1) will be clustered within cancer sites.
Although one would expect an increase in true cancer incidence to increase premature
cancer mortality, cancer incidence rates are subject to measurement error, so one should not
necessarily expect the coefficient on measured cancer incidence (γ) to be positive. Let I and
I* representmeasured and true cancer incidence, respectively. Then I = (I / I*)× I*, and log(I)
= log(I / I*) + log(I*). Measured cancer incidence can increase for two reasons: an increase
in true cancer incidence, or an increase in the ratio of measured incidence to true incidence.
The latter could occur as a result of increasing quantity or quality of cancer screening. More
and better cancer screening could lead to earlier diagnosis, which might reduce premature
mortality. Therefore the effect on premature mortality of increases in I* and increases in (I /
I*) may offset one another: the former is likely to increase premature mortality, but the latter
may reduce it. For this reason, although controlling (in an unrestrictive manner) for measured
incidence in the premature mortality model seems appropriate, we should not be surprised if
we don’t find a significant effect of measured incidence on premature mortality.
Estimation of Eq. (1) enables determination of how much of the decline in Canadian pre-
mature mortality during the sample period (2000–2011) can be attributed to the introduction
of new drugs. The expression (δ2011 – δ2000) indicates the 2000–2011 decline in prema-
6 The most recent available incidence data are for the year 2010.
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Fig. 4 Plot of the residuals from the unweighted regression [ln(YPLL75st) = αs + δt + εst] on the mean
premature mortality rate ((
∑
t YPLL75st)/12)
ture mortality, controlling for (holding constant) the number of drugs and cancer incidence,
i.e., in the absence of pharmaceutical innovation. Suppose Eq. (1) is estimated, excluding





2000) indicates the 2000–2011 decline in Canadian premature mortality, not holding
constant the number of drugs, i.e., in the presence of pharmaceutical innovation, and (δ′2011
– δ′2000) – (δ2011 – δ2000) is an estimate of the 2000–2011 decline in premature mortality
attributable to pharmaceutical innovation.
Themeasure of pharmaceutical innovation in Eq. (1)—the number of chemical substances
previously commercialized to treat a disease—is not the theoretically ideal measure. Pre-
mature mortality is presumably more strongly related to the drugs actually used to treat
a disease than it is to the drugs that could be used to treat the disease. A preferable
measure is the mean vintage of drugs used to treat a disease, defined as VINTAGEst =∑
d QdstLAUNCH_YEARd/
∑
d Qdst, where Qdst = the quantity of drug d used to treat
cancer at site s in year t, and LAUNCH_YEARd = the world launch year of drug d.7 Unfor-
tunately, measurement of VINTAGEst is infeasible: even though data on the total quantity of
each drug in each year (Qd.t = sQdst) are available, many drugs are used to treat multiple
diseases,8 and there is no way to determine the quantity of drug d used to treat cancer at
7 According to theMerriamWebster dictionary, one definition of vintage is “a period of origin or manufacture
(e.g. a piano of 1845 vintage)”. http://www.merriam-webster.com/dictionary/vintage. Robert Solow (1960)
introduced the concept of vintage into economic analysis. Solow’s basic idea was that technical progress
is “built into” machines and other goods and that this must be taken into account when making empirical
measurements of their roles in production. This was one of the contributions to the theory of economic growth
that the Royal Swedish Academy of Sciences cited when it awarded Solow the 1987 Alfred Nobel Memorial
Prize in Economic Sciences (Nobelprize.org 2015).
8 For example, dactinomycin is used to treat C45–C49 connective and soft tissue neoplasms, C51–C58 female
genital organ neoplasms, C60–C63 male genital organ neoplasms, and C64–C68 urinary organ neoplasms.
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site s in year t.9 However, it is shown in Appendix 1 of Lichtenberg (2014a) that there is a
highly significant positive correlation across drug classes between changes in the (quantity-
weighted) vintage of drugs and changes in the number of chemical substances previously
commercialized within the drug class.
Pharmaceutical innovation is not the only type of medical innovation that is likely to con-
tribute to premature mortality. Other medical innovation, such as innovation in diagnostic
imaging, surgical procedures, and medical devices, is also likely to affect premature mor-
tality. Therefore, measures of these other types of medical innovation should be included in
the Eq. (1). Unfortunately, longitudinal disease-level measures of non-pharmaceutical med-
ical innovation are not available for Canada. But failure to control for non-pharmaceutical
medical innovation is unlikely to bias estimates of the effect of pharmaceutical innovation on
premature mortality, for two reasons. First, pharmaceuticals are more research-intensive than
other types of medical care: in 2007, prescription drugs accounted for 10% of U.S. health
expenditure (Center for Medicare andMedicaid Services (2013, Table 2)), but more than half
of U.S. funding for biomedical research came from pharmaceutical and biotechnology firms
(Dorsey et al. 2010). Much of the rest came from the federal government (i.e. the NIH), and
new drugs often build on upstream government research (Sampat and Lichtenberg 2011).
The National Cancer Institute (2015b) says that it “has played an active role in the develop-
ment of drugs for cancer treatment for 50 years… [and] that approximately one half of the
chemotherapeutic drugs currently used by oncologists for cancer treatment were discovered
and/or developed” at the National Cancer Institute.
Second, previous research based on U.S. data indicates that non-pharmaceutical medical
innovation is not positively correlated across diseases with pharmaceutical innovation. In
Appendix 2 of Lichtenberg (2014a), it is shown that, in the U.S. during the period 1997–
2007, the rate of pharmaceutical innovation was not positively correlated across diseases
with the rate of medical procedure innovation and may have been negatively correlated with
the rate of diagnostic imaging innovation. Also, Lichtenberg (2014b) found that estimates of
the effect of pharmaceutical innovation on U.S. cancer mortality rates were insensitive to the
inclusion or exclusion of measures of non-pharmaceutical medical innovation. This suggests
that failure to control for other medical innovation is unlikely to result in overestimation of
the effect of pharmaceutical innovation on longevity growth.
In Eq. (1), premature mortality from cancer at site s in year t depends on the number
of new chemical entities (drugs) to treat cancer at site s registered in Canada by the end of
year t − k, i.e. there is a lag of k years. Equation (1) will be estimated for different values
of k: k = 0, 5, 10, 15, 20, 25.10 One would expect there to be a substantial lag because new
drugs diffuse gradually—they won’t be used widely until years after registration. Two kinds
of evidence—“within molecule” and “between molecule”—support the gradual diffusion
hypothesis. The first kind consists of estimates based on theπy parameters from the following
equation:
ln(SUmy) = ρm + πy + εmy (2)
9 Outpatient prescription drug claims usually don’t show the indication of the drug prescribed. Claims for
drugs administered by doctors and nurses (e.g. chemotherapy) often show the indication of the drug. In the US,
70% of spending on anticancer drugs is for drugs covered under the medical benefit and infused or injected.
However, t data on claims for drugs administered by doctors and nurses are not available for Canada.
10 A separate model is estimated for each value of k, rather than including multiple values (CUM_NCEi,t−1,
CUM_NCEi,t−2, CUM_NCEi,t−3,…) in a single model because CUM_NCE is highly serially correlated (by
construction), which would result in extremely high multicollinearity if multiple values were included.)
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Fig. 5 Estimates of the relative utilization index (year 0 = 1.0)
where, SUmy = the number of standard units11 of molecule m sold in Canada y years after
registration (y = 0, 1, …, 11); ρm = a fixed effect for molecule m; πy = a fixed effect for age
y
The expression exp(πy − π0) is a “relative utilization index”: it is the mean ratio of the
number of units of a molecule sold y years after registration to the number of units of the
same molecule sold in the year that it was registered. Using annual data on the number of
standard units of molecules sold in Canada during the period 1999–2010, I estimated Eq.
(2). Estimates of the “relative utilization index,” based on data on 25 molecules used to treat
cancer that were registered after 1998, are shown in Fig. 5. These estimates indicate that the
number of units sold 10 years after registration is about ten times as great as the number of
units sold one year after registration. Moreover, Fig. 5 provides a conservative estimate of
the slope of the age-utilization profile, because there was zero utilization of many of these
molecules in the first few years after they were registered.12
Figure 6 provides “between-molecule” evidence of gradual diffusion; it shows data on
the mean number of standard units of cancer drugs sold (in thousands) in Canada in 2010,
by period of registration in Canada. Mean utilization in 2010 of drugs registered after 2000
is only 15% as high as mean utilization of drugs registered during 1991–2000, and 17% as
high as mean utilization of drugs registered during 1981–1990.
The relatively low utilization of new drugs may be due to several factors. One is that the
prices of old drugs (most of which are no longer patent-protected) are considerably lower
than the prices of new, patent-protected drugs. A second factor may be that it takes time for
physicians to become knowledgeable about new treatment options. A third potential factor
is that new drugs may be targeted at smaller patient populations. Data from the U.S. Food
11 The number of standard ‘dose’ units sold is determined by taking the number of counting units sold divided
by the standard unit factor which is the smallest common dose of a product form as defined by IMS HEALTH.
For example, for oral solid forms the standard unit factor is one tablet or capsule whereas for syrup forms the
standard unit factor is one teaspoon (5 ml) and injectable forms it is one ampoule or vial. Other measures of
quantity, such as the number of patients using the drug, prescriptions for the drug, or defined daily doses of
the drug, are not available.
12 Since the dependent variable of Eq. (2) is logarithmic, observations for which SUmy = 0 had to be excluded.
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Fig. 6 Mean number of standard units of cancer drugs sold (in thousands) in 2010, by period of launch in
Canada
and Drug Administration (2015) indicate that drugs approved by the FDA since 2000 were
twice as likely to include pharmacogenomic information in their labeling as drugs approved
before 2000. A fourth potential factor is that older drugs are more likely to have supplemental
indications, i.e. indications approved after the drug was initially launched, than new drugs.13
The measure of pharmaceutical innovation, CUM_NCEs,t−k = ∑d INDds
REGISTEREDd,t−k, is based on whether drug d had an indication for cancer at site s at
the end of 2011. One would prefer to base the measure on whether drug d had an indication
for cancer at site s at the end of year t-k. FDA data indicate that about one in four new
molecular entities has supplemental indications, i.e. indications approved after the drug was
initially registered.14
In Eq. (1), the measure of premature mortality is the number of years of potential life
lost before age 75. This is the age threshold used in Statistics Canada’s key socioeconomic
database (CANSIM). Other authorities use different age thresholds; the CDC (2013) provides
estimates of YPLL before ages 65, 70, 75, 80, and 85. To assess the robustness of my results,
I will estimate models similar to Eq. (1), using age thresholds 65 and 55 as well as 75.
Chemical substances are divided into different groups according to the organ or sys-
tem on which they act and their therapeutic, pharmacological and chemical properties. In
the Anatomical Therapeutic Chemical (ATC) classification system developed by the World
Health Organization Collaborating Centre for Drug Statistics Methodology, drugs are clas-
sified in groups at five different levels. The highest (1s) level is the “anatomical main group”
13 The measure of pharmaceutical innovation, CUM_NCEs,t−k = d INDds REGISTEREDd,t−k, is based
on whether drug d had an indication for cancer at site s at the end of 2011. One would prefer to base the
measure on whether drug d had an indication for cancer at site s at the end of year t - k. Data in the U.S. FDA’s
Drugs@FDA data files indicate that about one in four new molecular entities has supplemental indications,
i.e. indications approved after the drug was initially launched.
14 Source: Drugs@FDA Data Files.
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level; there are 14 anatomical main groups. The 2nd, 3rd, 4th, and 5th levels are “therapeutic
subgroup,” “pharmacological subgroup,” “chemical subgroup,” and “chemical substance,”
respectively.15
Premature mortality from a disease may depend on the number of chemical (or pharma-
cological) subgroups that have previously been developed to treat the disease rather than, or
in addition to, the number of chemical substances (drugs) that have previously been devel-
oped to treat the disease. This will be investigated by estimating versions of Eq. (1) in which






IND_SUBGROUPgs = 1 if any drugs in chemical subgroup g are
used to treat (indicated for) cancer at site s
= 0 if no drugs in chemical subgroup g are used to treat
(indicated for) cancer at site s
REGISTERED_SUBGROUPg,t−k = 1 if any drugs in chemical subgroup g had been
registered in Canada by the end of year t − k
= 0 if no drugs in chemical subgroup g had been
registered in Canada by the end of year t − k
3 Data
NCE registrations in Canada (REGISTERED). Data on new chemical entities registered in
Canada were constructed from the Health Canada Drug Product Database, which contains
product-specific information on drugs approved for use in Canada. The database is managed
by Health Canada and includes human pharmaceutical and biological drugs, veterinary drugs
and disinfectant products. It contains approximately 15,000 products which companies have
notified Health Canada as being marketed.
Drug indications (IND). Data on drug indications were obtained from Thériaque, a data-
base of official, regulatory, and bibliographic information on all drugs available in France,
intended for health professionals. This database is produced by the Centre National Hospi-
15 For example, the five levels associated with the chemical subgroup “nitrogen mustard analogues” are:
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01A ALKYLATING AGENTS
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L01BB07 Nelarabine 2007 x
L01XA03 Oxaliplan 2007 x x
L01XE06 Dasanib 2007 x
L01XE09 Temsirolimus 2007 x
L01XC08 Panitumumab 2008 x x
L01XE08 Nilonib 2008 x
L04AX04 Lenalidomide 2008 x
L01BB06 Clofarabine 2009 x
L01BC07 Azacidine 2009 x
L01XD03 Methyl aminolevulinate 2009 x
L01XE07 Lapanib 2009 x
L02BX02 Degarelix 2009 x
J07BM02 Papillomavirus (human 
types 16, 18)
2010 x
L01CX01 Trabectedin 2010 x x
L01XE11 Pazopanib 2010 x
L04AX02 Thalidomide 2010 x
L01XX41 Eribulin 2011 x
L02BX03 Abiraterone 2011 x
L03AX16 Plerixafor 2011 x
L01AA09 Bendamusne 2012 x x
L01XC10 Ofatumumab 2012 x
L01XC11 Ipilimumab  2012 x
L01XX27 Arsenic trioxide 2013 x
and related ssue
talier d’Information sur le Médicament. In this database, drugs are coded according to WHO
ATC codes, and diseases are coded according toWHO ICD-10 codes.16 The drug indications
listed in Thériaque are labeled indications, as defined by the Collège de la Haute autorité de
Santé.
Table 1 shows drugs (sorted by registration year) launched after 2006 used to treat various
types of cancer in Canada. Appendix Table 1 in supplementary material shows drugs (sorted
by registration year) launched since 1951 used to treat various types of cancer in Canada.
Premature mortality data (YPLL75, YPLL65, YPLL55). Data on years of potential life lost
before ages 75, 65, and 55, by cancer site and year (2000–2011), were constructed from the
WHOMortality Database, a compilation of mortality data by age, sex and cause of death, as
reported annually by Member States from their civil registration systems.17
16 Many drug databases contain information about drug indications, but this information is usually in text
form only.
17 Mortality data are reported in 5-year age groups in the WHOMortality Database. I assume that deaths in a
5-year age group occur at the midpoint of the age group. For example, I assume that deaths at age 35–39 years
occurred at age 37.5. The Association of Public Health Epidemiologists in Ontario (2015) uses this method.
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Table 2 Estimates of the βk parameters from Eq. (1) and similar equations
Model Parameter Lag Estimate SE Z Pr > |Z|
A. Dependent variable: ln(YPLL75st) Weight: ((
∑
t YPLL75it) / 12)
1 β0 0 −0.003 0.009 −0.33 0.7385
2 β5 5 −0.006 0.008 −0.73 0.4659
3 β10 10 −0.013 0.003 −4.69 <0.0001
4 β15 15 −0.021 0.002 −8.96 <0.0001
5 β20 20 −0.019 0.003 −7.58 <0.0001
6 β25 25 −0.023 0.003 −8.09 <0.0001
B. Dependent variable: ln(YPLL65st) Weight: ((
∑
t YPLL65it) / 12)
7 β0 0 −0.006 0.009 −0.61 0.5427
8 β5 5 −0.006 0.007 −0.88 0.3784
9 β10 10 −0.012 0.003 −4.80 <0.0001
10 β15 15 −0.023 0.003 −6.78 <0.0001
11 β20 20 −0.022 0.003 −8.72 <0.0001
12 β25 25 −0.026 0.003 −10.74 <0.0001
C. Dependent variable: ln(YPLL55st) Weight: ((
∑
t YPLL55it) / 12)
13 β0 0 −0.013 0.009 −1.43 0.1519
14 β5 5 −0.014 0.009 −1.62 0.1045
15 β10 10 −0.016 0.005 −3.19 0.0014
16 β15 15 −0.024 0.004 −6.10 <0.0001
17 β20 20 −0.025 0.004 −6.92 <0.0001
18 β25 25 −0.029 0.005 −5.53 <0.0001
Each estimate was obtained from a separate model. All equations include a cancer incidence measure (e.g.
ln(INC_RATE75st)), cancer-site fixed effects and year fixed effects. Standard errors are clusteredwithin cancer
sites
Cancer incidence data. Data on the number of new cancer cases, by cancer site, age, and
year, were obtained from CANSIM Table 103-0550.
Population data. Data on population, by age and year, were obtained from
CANSIM Table 051-0001.
4 Empirical results
Estimates of the βk parameters from Eq. (1) and similar equations are shown in Table 2 and
plotted (on an inverted scale) in Fig. 7. Each estimate was obtained from a separate model.
All equations include a cancer incidencemeasure (e.g. ln(INC_RATE75st)), cancer-site fixed
effects and year fixed effects. To conserve space and simplify the presentation, estimates of
the cancer incidence coefficient (γ) are not included in Table 2.18 None of the estimates of
this coefficient were statistically significant, and controlling for cancer incidence had very
little effect on the estimates of βk. As discussed earlier, this may be due to offsetting effects
of increases in I* and increases in (I / I*) on premature mortality.
18 Complete estimates of model 4 are presented in Appendix Table 4.
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Age threshold = 55
Fig. 7 Estimates of the βk parameters from Eq. (1) and similar equations
In part A of Table 2 and Fig. 7, the age threshold for calculating premature mortality is 75
years, i.e. the dependent variable is years of potential life lost before age 75. In model 1, the
lag (k) from drug registrations to premature mortality equals zero, i.e. we are examining the
effect of the cumulative number of drugs registered by the end of year t on prematuremortality
in year t. The estimate of β0 is not statistically significant. In model 2, the lag is 5 years; the
estimate of β5 is also statistically insignificant. In models 3–6, the lags are 10, 15, 20, and 25
years, respectively. All of these coefficients are negative and highly statistically significant (p
value <0.0001), indicating that premature mortality before age 75 is significantly inversely
related to the cumulative number of drugs registered at least 10 years earlier. The estimate
of β15 is the most statistically significant, and the magnitude of the point estimate of β15 is
66% larger than the magnitude of the point estimate of β10. Since, as discussed earlier, mean
utilization of drugs that have been marketed for less than 10 years is only one-sixth as great
as mean utilization of drugs that have been marketed for at least a decade, it is not surprising
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C00-C14 lip, oral cavity and pharynx
C15-C26 digestive organs
C30-C39 respiratory system and
intrathoracic organs
C40-C41 bone and articular cartilage
C43-C44 skin
C45-C49 connective and soft tissue
C50-C50 breast
C51-C58 female genital organs
C60-C63 male genital organs
C64-C68 urinary organs
C69-C72 eye, brain and central nervous
system
C73-C75 endocrine glands and related
structures
C76-C80 secondary and ill-defined
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The bubble size is proportional to the mean premature mortality rate during 2000-2011 (( t YPLL75it) / 12).Σ
Fig. 8 Relationship across cancer sites between the number of drugs launched during 1985–1996 and the
2000–2011 log change in the premature (before age 75 ) mortality rate
that premature mortality is strongly inversely related only to the cumulative number of drugs
that had been registered at least ten years earlier.
In partsB andCofTable 2 andFig. 7, the age thresholds for calculating prematuremortality
are 65 years and 55 years, respectively. The estimates based on these age thresholds are very
similar to the estimates based on the age threshold of 75 years: premature mortality before
age 65 and 55 is strongly inversely related only to the cumulative number of drugs that had
been registered at least ten years earlier.
Figure 8 shows a bubble plot of the long-run (2000–2011) log change in YPLL before age
75 [ln(YPLL75s,2011)− ln(YPLL75s,2000)] against the long-run change in the cumulative
number of drugs registered 15 years earlier [CUM_NCEs,1996− CUM_NCEs,1985], i.e. the
number of drugs registered during the period 1985–1996. The bubble size is proportional
to the mean premature mortality rate during 2000–2011 ((t YPLL75it) / 12). This figure
confirms the finding from model 4 in Table 2 of a highly significant inverse relationship. The
point estimate of β15 from the long-difference model (β15 = −0.0247, t value = −4.42; p
value = 0.0010) is similar to the point estimate of β15 from model 4 in Table 2.
Figure 8 reveals that the largest number of drugs that were launched during 1985–1996
were for cancers of lymphoid, haematopoietic and related tissue (ICD-10 block C81–C96),
which include leukemia. In principle, it is possible that excluding this ICD-10 block could
have a substantial effect on the estimates, although it does not appear from Fig. 8 to be an
outlier. As shown in Appendix Table 5, when ICD-10 block C81-C96 is excluded from the
sample, estimates of Eq. (1) are very similar to the estimates when it is included.
As discussed above, the hypothesis that premature mortality from a disease depends on
the number of chemical (or pharmacological) subgroups that have previously been devel-
oped to treat the disease rather than, or in addition to, the number of chemical substances
(drugs) that have previously been developed to treat the disease can be tested by estimating
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Table 3 Estimates of models of years of potential life lost before age 75, including cumulative number of




Model Regressor Estimate SE Z Pr > |Z|
4 CUM_NCEs,t−15 −0.021 0.002 −8.96 <0.0001
19 CUM_SUBGROUPs,t−15 −0.023 0.009 −2.55 0.0107
20 CUM_NCEs,t−15 −0.024 0.004 −6.78 <0.0001
20 CUM_SUBGROUPs,t−15 0.010 0.012 0.83 0.4042
All equations include a cancer incidence measure (e.g. ln(INC_RATE75st)), cancer-site fixed effects and year
fixed effects. Standard errors are clustered within cancer sites
versions of Eq. (1) in which CUM_SUBGROUPs,t−k is included instead of, or in addition to,
CUM_NCEs,t−k. Table 3 provides estimates of models suitable for testing this hypothesis.
Estimates from three different models are presented there. In all three models, the depen-
dent variable is ln(YPLL75st) and k = 15. The first model shown is the same as model 4
in Table 2, in which the only pharmaceutical variable is CUM_NCEs,t−15. In the second
model (model 19), CUM_NCEs,t−15 is replaced by CUM_SUBGROUPs,t−15. The coeffi-
cient on this variable is negative and significant, but it is less significant than the coefficient
on CUM_NCEs,t−15 in model 4. The third model (model 20) includes both CUM_NCEs,t−15
and CUM_SUBGROUPs,t−15. Controlling for the cumulative number of drugs, the cumu-
lative number of chemical subgroups is not statistically significant. These estimates suggest
that drugs (chemical substances) within the same class (chemical subgroup) are not “thera-
peutically equivalent,”19 i.e. they do not have essentially the same effect in the treatment of
a disease or condition.
5 Discussion
During the period 2000–2011, the premature (before age 75) cancermortality rate (the number
of years of potential life lost due to cancer before age 75 per 100,000 population age 0–74)
declined by about 9%. The estimates of model 4 imply that, in the absence of pharmaceutical
innovation during the period 1985–1996, the premature cancer mortality rate would have
increased about 12% during the period 2000–2011.20, 21 As shown in Fig. 9, the premature
mortality rate would have been 1788, rather than its actual value of 1459. In 2011, the
population age 0–74 was about 32.1 million (or 321 hundred thousand), so the estimates of
model 4 imply that pharmaceutical innovation during the period 1985–1996 reduced the
number of years of potential life lost to cancer before age 75 in 2011 by 105,366 (= 321 *
(1788 – 1459)).
19 According to one medical dictionary, drugs that have “essentially the same effect in the treatment of a
disease or condition” are therapeutically equivalent. Drugs that are therapeutically equivalent may or may not
be chemically equivalent, bioequivalent, or generically equivalent. http://medical-dictionary.thefreedictionary.
com/therapeutic+equivalent.
20 In Appendix Table 4, the point estimate of δ2000 is −0.1157 (p value = 0.0003). If CUM_NCEs,t−15 is
excluded from the equation, the point estimate of δ2000 is 0.0873 (p value = 0.0008).
21 An important possible reason why the premature cancer mortality rate would have increased in the absence
of previous pharmaceutical innovation is a substantial decline in the “competing risk” of death from cardio-
vascular disease. See Honoré and Lleras-Muney (2006).
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The premature (before age 75) cancer mortality rate is the number of years of potential life lost due to cancer before age 75 per
100,000 population age 0-74.
Fig. 9 Premature (before age 75) cancer mortality rate: actual versus estimated in the absence of previous
pharmaceutical innovation
This reduction in premature mortality is an estimate of the benefit to Canadians below
age 75 in 2011 of pharmaceutical innovation during the period 1985–1996. Now I will
calculate an estimate of the (social) cost of this innovation. As shown in Appendix Table 1
in supplementary matrial, 40 drugs that are used to treat cancer were registered during the
period 1985–1996. Data from IMS Health indicate that in 2010,22 expenditure on products
containing these molecules was 409 million USD, which is about 1.9% of total Canadian
drug expenditure (21.6 billion USD). About 70% of cancer patients were diagnosed before
the age of 75, so it seems reasonable to assume that 288 million USD (= 70% * 409 million
USD) was spent on these drugs for cancer patients below the age of 75.23 This implies that
the cost per life-year before age 75 gained from previous pharmaceutical innovation was
2730 USD (= 288 million USD / 105,366 life-years).
Presumably most of the drugs registered during the period 1985–1996 were off-patent by
2010, so these cost estimates reflect prices of generic drugs. Law (2013) argues that Canadian
generic drug prices have traditionally been set using a percentage of the equivalent brand-
name price as a ceiling, and that typically, these percentages ranged between 60 and 70%
of the brand price.24 This suggests that if these drugs had been sold at branded rather than
generic prices, the cost per life-year gained would have been between 3900 (= 2730 / 60%)
and 4550 (= 2730 / 70%) USD. However, the ratio of generic price to branded price may
be significantly lower for cancer drugs (which are often infused or injected) than it is for
other drugs (which are primarily administered orally). For example, when imatinib, which
is used to treat a set of leukemias, went generic in Canada in 2013, the generic drug price
was approximately 25% of the branded price. If the generic/branded price ratio were 25%,
22 2010 is the most recent year for which these data are available.
23 Since some of these drugs are used to treat diseases other than cancer, this is probably an overestimate.
24 Law (2013) also argues that recent changes havemoved these price ceilings lower in almost every province,
to a nationwide low of 25% in Ontario.
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and if these drugs had been sold at branded rather than generic prices, the cost per life-year
gained would have been 10,920 (= 2730 / 25%) USD.
Hirth et al. (2000) performed a search of the value-of-life literature and identified 41 esti-
mates of the value of life from37 articles.25 Fromestimates of the value of life, they calculated
estimates of the value (in 1997 dollars) of a quality-adjusted life-year (QALY).26 Four types
of methods were used to produce those estimates: revealed preference/job risk, contingent
valuation, revealed preference/non-occupational safety, and human capital. Median implied
values (in 1997 and 2011 dollars27) of a QALY estimated in those studies are shown in the
following table.
Study method Number of studies Median value of a QALY
1997 dollars 2011 dollars
Revealed preference/job risk 19 $428,286 $600,243
Contingent valuation 8 $161,305 $226,069
Revealed preference/non-occupational safety 8 $93,402 $130,903
Human capital 6 $24,777 $34,725
My estimate of the cost per life-year before age 75 gained from previous pharmaceutical
innovation is well below even the lowest estimates of the value of a life-year saved.
6 Summary and conclusions
The premature cancer mortality rate has been declining in Canada, and there has been
considerable variation in the rate of decline across cancer sites. I analyzed the effect that phar-
maceutical innovation has had on premature cancer mortality in Canada during the period
2000–2011, by investigating whether the cancer sites that experienced more pharmaceutical
innovation had larger declines in the premature mortality rate, controlling for changes in the
incidence rate.
The study is subject to several limitations. First, themeasures of pharmaceutical innovation
that were used were based only on labeled indications, but the National Cancer Institute
(2015d) says that “off-label use of drugs is very common in cancer treatment.” Second, it
was not possible to measure or control for non-pharmaceutical medical innovation. Third,
the outcome measures used were life-years gained, not quality-adjusted life-years gained.
The estimates indicated that premature mortality before age 75 is significantly inversely
related to the cumulative number of drugs registered at least 10 years earlier. Since mean
utilization of drugs that have been marketed for less than 10 years is only one-sixth as great
as mean utilization of drugs that have been marketed for at least a decade, it is not surprising
that premature mortality is strongly inversely related only to the cumulative number of drugs
25 Twenty-eight of the reviewed articles used U.S. data; the remaining articles used data from the U.K. (4),
Canada (3), France (1), and Denmark (1). National origin did not significantly affect the values.
26 Lichtenberg (2009) demonstrated that, although the health of cancer patients is less than perfect, the
number of QALYs gained from pharmaceutical innovation could be either greater than or less than the number
of life-years gained.
27 The U.S. Consumer Price Index increased by 40% between 1997 and 2011.
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that had been registered at least ten years earlier. Premature mortality before age 65 and 55
is also strongly inversely related to the cumulative number of drugs that had been registered
at least ten years earlier. None of the estimates of the effect of incidence on mortality were
statistically significant.
Controlling for the cumulative number of drugs, the cumulative number of chemical sub-
groups does not have a statistically significant effect on premature mortality. This suggests
that drugs (chemical substances) within the same class (chemical subgroup) are not thera-
peutically equivalent.
During the period 2000–2011, the premature (before age 75) cancermortality rate declined
by about 9%. The estimates imply that, in the absence of pharmaceutical innovation dur-
ing the period 1985–1996, the premature cancer mortality rate would have increased about
12% during the period 2000–2011. A substantial decline in the “competing risk” of death
from cardiovascular disease could account for this. The estimates imply that pharmaceutical
innovation during the period 1985–1996 reduced the number of years of potential life lost to
cancer before age 75 in 2011 by 105,366.
The cost per life-year before age 75 gained from previous pharmaceutical innovation is
estimated to have been 2730 USD. Most of the previously-registered drugs were off-patent
by 2011, but evidence suggests that, even if these drugs had been sold at branded rather than
generic prices, the cost per life-year gained would have been below 11,000 USD, a figure
well below even the lowest estimates of the value of a life-year gained.
The largest reductions in premature mortality occur at least a decade after drugs are
registered, when their utilization increases significantly. This suggests that, if Canada is to
obtain substantial additional reductions in premature cancer mortality in the future (a decade
or more from now) at a modest cost, pharmaceutical innovation (registration of new drugs)
is needed today.
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Appendix
See Tables 4 and 5.
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Table 4 Complete estimates of model 4 Dependent variable: ln(YPLL75st) Weight: ((
∑
t YPLL75it) / 12)
Parameter Estimate SE Z Pr > |Z|
CUM_NCEs,t−15 −0.021 0.002 −8.96 <0.0001
ln(INC_RATE75st) 0.064 0.116 0.55 0.5831
Year 2000 −0.116 0.032 −3.61 0.0003
Year 2001 −0.113 0.036 −3.16 0.0016
Year 2002 −0.118 0.035 −3.38 0.0007
Year 2003 −0.121 0.029 −4.25 <0.0001
Year 2004 −0.095 0.026 −3.68 0.0002
Year 2005 −0.072 0.022 −3.35 0.0008
Year 2006 −0.079 0.019 −4.12 <0.0001
Year 2007 −0.042 0.016 −2.60 0.0092
Year 2008 −0.044 0.021 −2.10 0.0359
Year 2009 −0.049 0.022 −2.18 0.0290
Year 2010 −0.016 0.015 −1.08 0.2821
Year 2011 0.000 0.000 – –
group C00–C14 lip, oral cavity and
pharynx
−2.154 0.156 −13.81 <0.0001
group C15–C26 digestive organs 0.285 0.116 2.45 0.0141
group C30–C39 respiratory system
and intrathoracic organs
0.567 0.085 6.70 <0.0001
group C40–C41 bone and articular
cartilage
−3.028 0.403 −7.52 <0.0001
group C43–C44 skin −2.048 0.124 −16.47 <0.0001
group C45–C49 connective and soft
tissue
−1.979 0.248 −7.98 <0.0001
group C50–C50 breast −0.434 0.089 −4.90 <0.0001
group C51–C58 female genital
organs
−1.011 0.060 −16.87 <0.0001
group C60–C63 male genital organs −2.132 0.089 −23.94 <0.0001
group C64–C68 urinary organs −1.481 0.065 −22.75 <0.0001
group C69–C72 eye, brain and
central nervous system
−1.069 0.169 −6.31 <0.0001
group C73–C75 endocrine glands
and related structures
−3.277 0.143 −22.93 <0.0001
group C76–C80 secondary and
ill-defined
−0.965 0.123 −7.82 <0.0001
group C81–C96 stated or presumed
to be primary, of lymphoid,
haematopoietic and related tissue
0.000 0.000 – –
Intercept 5.730 0.397 14.44 <0.0001
Standard errors are clustered within cancer sites
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